Bhumsuk Keam
Bhumsuk Keam
Department of Internal Medicine, Seoul National University Hospital
Verified email at
Cited by
Cited by
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ...
Journal of Clinical Oncology 34 (32), 3838, 2016
Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ...
Journal of Clinical Oncology 36 (1), 7, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ...
British journal of cancer 119 (2), 153-159, 2018
Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas
JK Lee, J Lee, S Kim, S Kim, J Youk, S Park, Y An, B Keam, DW Kim, ...
Journal of clinical oncology 35 (26), 3065-3074, 2017
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ...
Annals of Oncology 29 (8), 1807-1813, 2018
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ...
Breast Cancer Research 13, 1-7, 2011
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
RL Ferris, R Haddad, C Even, M Tahara, M Dvorkin, TE Ciuleanu, ...
Annals of Oncology 31 (7), 942-950, 2020
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the …
B Keam, SA Im, HJ Kim, DY Oh, JH Kim, SH Lee, EK Chie, W Han, ...
BMC cancer 7, 1-11, 2007
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ...
The lancet Diabetes & endocrinology 9 (8), 491-501, 2021
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
CY Ock, B Keam, S Kim, JS Lee, M Kim, TM Kim, YK Jeon, DW Kim, ...
Clinical cancer research 22 (9), 2261-2270, 2016
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ...
Cancer discovery 8 (7), 812-821, 2018
Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor
TM Kim, A Song, DW Kim, S Kim, YO Ahn, B Keam, YK Jeon, SH Lee, ...
Journal of Thoracic Oncology 10 (12), 1736-1744, 2015
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
SH Lee, JK Lee, MJ Ahn, DW Kim, JM Sun, B Keam, TM Kim, DS Heo, ...
Annals of Oncology 28 (2), 292-297, 2017
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer
S Kim, TM Kim, DW Kim, H Go, B Keam, SH Lee, JL Ku, DH Chung, ...
Journal of Thoracic Oncology 8 (4), 415-422, 2013
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
TM Kim, JC Paeng, IK Chun, B Keam, YK Jeon, SH Lee, DW Kim, DS Lee, ...
Cancer 119 (6), 1195-1202, 2013
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
MS Brose, B Robinson, SI Sherman, J Krajewska, CC Lin, F Vaisman, ...
The Lancet Oncology 22 (8), 1126-1138, 2021
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non–small cell lung cancer harboring wild-type epidermal growth factor receptor: a …
JK Lee, S Hahn, DW Kim, KJ Suh, B Keam, TM Kim, SH Lee, DS Heo
Jama 311 (14), 1430-1437, 2014
Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study
RB Cohen, JP Delord, T Doi, SA Piha-Paul, SV Liu, J Gilbert, AP Algazi, ...
American journal of clinical oncology 41 (11), 1083-1088, 2018
The system can't perform the operation now. Try again later.
Articles 1–20